[go: up one dir, main page]

UY29405A1 - IVABRADINE CHLORHYDRATE BETA CRYSTAL FORM, ITS PREPARATION PROCEDURE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN IT. - Google Patents

IVABRADINE CHLORHYDRATE BETA CRYSTAL FORM, ITS PREPARATION PROCEDURE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN IT.

Info

Publication number
UY29405A1
UY29405A1 UY29405A UY29405A UY29405A1 UY 29405 A1 UY29405 A1 UY 29405A1 UY 29405 A UY29405 A UY 29405A UY 29405 A UY29405 A UY 29405A UY 29405 A1 UY29405 A1 UY 29405A1
Authority
UY
Uruguay
Prior art keywords
contain
pharmaceutical compositions
crystal form
preparation procedure
beta crystal
Prior art date
Application number
UY29405A
Other languages
Spanish (es)
Inventor
Marie-Noelle Auguste
Gerard Damien
Stephane Horvath
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34954954&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY29405(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of UY29405A1 publication Critical patent/UY29405A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • D—TEXTILES; PAPER
    • D21—PAPER-MAKING; PRODUCTION OF CELLULOSE
    • D21H—PULP COMPOSITIONS; PREPARATION THEREOF NOT COVERED BY SUBCLASSES D21C OR D21D; IMPREGNATING OR COATING OF PAPER; TREATMENT OF FINISHED PAPER NOT COVERED BY CLASS B31 OR SUBCLASS D21G; PAPER NOT OTHERWISE PROVIDED FOR
    • D21H27/00—Special paper not otherwise provided for, e.g. made by multi-step processes
    • D21H27/10—Packing paper
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
    • B65D81/18—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents providing specific environment for contents, e.g. temperature above or below ambient
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D85/00—Containers, packaging elements or packages, specially adapted for particular articles or materials
    • B65D85/30—Containers, packaging elements or packages, specially adapted for particular articles or materials for articles particularly sensitive to damage by shock or pressure
    • D—TEXTILES; PAPER
    • D21—PAPER-MAKING; PRODUCTION OF CELLULOSE
    • D21H—PULP COMPOSITIONS; PREPARATION THEREOF NOT COVERED BY SUBCLASSES D21C OR D21D; IMPREGNATING OR COATING OF PAPER; TREATMENT OF FINISHED PAPER NOT COVERED BY CLASS B31 OR SUBCLASS D21G; PAPER NOT OTHERWISE PROVIDED FOR
    • D21H21/00—Non-fibrous material added to the pulp, characterised by its function, form or properties; Paper-impregnating or coating material, characterised by its function, form or properties
    • D21H21/14—Non-fibrous material added to the pulp, characterised by its function, form or properties; Paper-impregnating or coating material, characterised by its function, form or properties characterised by function or properties in or on the paper
    • D21H21/16—Sizing or water-repelling agents
    • D—TEXTILES; PAPER
    • D21—PAPER-MAKING; PRODUCTION OF CELLULOSE
    • D21H—PULP COMPOSITIONS; PREPARATION THEREOF NOT COVERED BY SUBCLASSES D21C OR D21D; IMPREGNATING OR COATING OF PAPER; TREATMENT OF FINISHED PAPER NOT COVERED BY CLASS B31 OR SUBCLASS D21G; PAPER NOT OTHERWISE PROVIDED FOR
    • D21H27/00—Special paper not otherwise provided for, e.g. made by multi-step processes
    • D21H27/30—Multi-ply
    • D21H27/40—Multi-ply at least one of the sheets being non-planar, e.g. crêped

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mechanical Engineering (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Forma cristalina B de cloruro de ivabradina, caracterizado por su espectro de difracción de rayos X sobre polvo, útiles en el tratamiento de situaciones clínicas de isquemia miocádica, en distintas patologías que implican trastornos del ritmo cardíaco y en la insuficiencia cardíaca.Crystalline form B of ivabradine chloride, characterized by its X-ray powder diffraction spectrum, useful in the treatment of clinical situations of myocardial ischemia, in different pathologies that involve heart rhythm disorders and heart failure.

UY29405A 2005-02-28 2006-02-24 IVABRADINE CHLORHYDRATE BETA CRYSTAL FORM, ITS PREPARATION PROCEDURE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN IT. UY29405A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0501985A FR2882553B1 (en) 2005-02-28 2005-02-28 CRYSTALLINE BETA FORM OF IVABRADINE HYDROCHLORIDE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME

Publications (1)

Publication Number Publication Date
UY29405A1 true UY29405A1 (en) 2006-07-31

Family

ID=34954954

Family Applications (1)

Application Number Title Priority Date Filing Date
UY29405A UY29405A1 (en) 2005-02-28 2006-02-24 IVABRADINE CHLORHYDRATE BETA CRYSTAL FORM, ITS PREPARATION PROCEDURE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN IT.

Country Status (43)

Country Link
US (3) US7361649B2 (en)
EP (1) EP1695965B9 (en)
JP (1) JP4625776B2 (en)
KR (1) KR100827502B1 (en)
CN (1) CN1827600B (en)
AP (1) AP1907A (en)
AR (1) AR053147A1 (en)
AT (1) ATE407926T1 (en)
BR (1) BRPI0600623A (en)
CA (1) CA2537414C (en)
CO (1) CO5770096A1 (en)
CR (1) CR8248A (en)
CU (1) CU23614B7 (en)
CY (1) CY1109072T1 (en)
DE (1) DE602006002624D1 (en)
DK (1) DK1695965T3 (en)
EA (1) EA008464B1 (en)
EC (2) ECSP066375A (en)
ES (1) ES2313581T3 (en)
FR (1) FR2882553B1 (en)
GE (1) GEP20084465B (en)
GT (1) GT200600084A (en)
HK (1) HK1096387A1 (en)
HR (1) HRP20080520T3 (en)
IL (1) IL173957A0 (en)
JO (1) JO2548B1 (en)
MA (1) MA28131A1 (en)
ME (1) ME01408B (en)
MY (1) MY158128A (en)
NO (1) NO338370B1 (en)
NZ (1) NZ545576A (en)
PE (1) PE20061009A1 (en)
PL (1) PL1695965T3 (en)
PT (1) PT1695965E (en)
RS (1) RS50661B (en)
SA (1) SA06270038B1 (en)
SG (1) SG125228A1 (en)
SI (1) SI1695965T1 (en)
TW (1) TWI314144B (en)
UA (1) UA80904C2 (en)
UY (1) UY29405A1 (en)
WO (1) WO2006092493A1 (en)
ZA (1) ZA200601762B (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2868777B1 (en) * 2004-04-13 2006-05-26 Servier Lab NOVEL PROCESS FOR THE SYNTHESIS OF IVABRADINE AND ITS SALTS OF ADDITION TO A PHARMACEUTICALLY ACCEPTABLE ACID
FR2882556B1 (en) * 2005-02-28 2007-05-04 Servier Lab CRYSTALLINE GAMMA D FORM OF IVABRADINE HYDROCHLORIDE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
FR2882555B1 (en) * 2005-02-28 2007-05-04 Servier Lab CRYSTALLINE GAMMA FORM OF IVABRADINE HYDROCHLORIDE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
FR2882553B1 (en) * 2005-02-28 2007-05-04 Servier Lab CRYSTALLINE BETA FORM OF IVABRADINE HYDROCHLORIDE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
FR2882554B1 (en) * 2005-02-28 2007-05-04 Servier Lab IVABRADINE HYDROCHLORIDE BETA D-CRYSTALLINE FORM, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
FR2891826B1 (en) * 2005-10-11 2007-12-28 Servier Lab CRYSTALLINE FORM 6 OF IVABRADINE HYDROCHLORIDE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
FR2891827B1 (en) * 2005-10-11 2007-12-28 Servier Lab CRYSTALLINE DELTAD FORM OF IVABRADINE HYDROCHLORIDE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
FR2894825B1 (en) * 2005-12-21 2010-12-03 Servier Lab NOVEL ASSOCIATION OF SINUSAL IF CURRENT INHIBITOR AND CONVERSION ENZYME INHIBITOR AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
EP2460797A3 (en) 2006-11-30 2012-12-05 Cadila Healthcare Limited Process for preparation of ivabradine hydrochloride
FR2911279B1 (en) * 2007-01-11 2009-03-06 Servier Lab USE OF IVABRADINE FOR THE PRODUCTION OF MEDICAMENTS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION
CN101353325B (en) * 2007-07-27 2011-11-09 上海优拓医药科技有限公司 Stable Ivabradine crystal and preparation thereof
RU2473544C2 (en) 2007-05-30 2013-01-27 Инд-Свифт Лабораториз Лимитед Method of producing ivabradine hydrochloride and polymorphs thereof
FR2938194B1 (en) * 2008-11-07 2012-08-31 Servier Lab USE OF IVABRADINE AS A DIAGNOSTIC AGENT IN CORONARY ANGIOGRAPHY THROUGH MULTICOUTE TOMODENSITOMETRY
WO2010072409A1 (en) 2008-12-22 2010-07-01 Krka, D. D., Novo Mesto Process for preparation of ivabradine
CN101774969B (en) * 2009-01-13 2012-07-04 江苏恒瑞医药股份有限公司 Ivabradine sulfate and method for preparing type I crystal thereof
HUE035588T2 (en) 2010-02-12 2018-05-28 Krka D D Novo Mesto Form of ivabradine hydrochloride
HUP1000245A2 (en) 2010-05-07 2011-11-28 Richter Gedeon Nyrt Industrial process for the production ivabradin salts
TWI499587B (en) * 2010-06-03 2015-09-11 Jiangsu Hengrui Medicine Co Method for the preparation of ivabradine sulfate and form i thereof
US20130084335A1 (en) 2010-06-14 2013-04-04 Ratiopharm Gmbh Ivabradine-containing pharmaceutical composition
WO2012025940A1 (en) 2010-08-25 2012-03-01 Cadila Healthcare Limited Polymorphic form of ivabradine hydrochloride and process for preparation thereof
CN102304088B (en) * 2011-07-07 2013-06-19 石药集团欧意药业有限公司 Ivabradine compound, preparation method and pharmaceutical composition thereof
US9440924B2 (en) 2011-08-02 2016-09-13 Sandoz Ag Acetone solvate of ivabradine hydrochloride
EP2589594A1 (en) 2011-11-04 2013-05-08 Urquima S.A. Ivabradine hydrochloride Form IV
WO2013064427A1 (en) 2011-11-04 2013-05-10 Synthon Bv A process for making crystalline delta-form of ivabradine hydrochloride
WO2013102919A1 (en) 2011-11-14 2013-07-11 Cadila Healthcare Limited Polymorphic forms of ivabradine hydrochloride
US9409913B2 (en) * 2012-11-21 2016-08-09 Enaltec Labs Private Limited Polymorphic forms of alcaftadine
WO2014114341A1 (en) 2013-01-24 2014-07-31 Synthon Bv Process for making ivabradine
HRP20200300T4 (en) 2013-03-19 2023-09-15 Chemo Research, S.L. New polymorph of ivabradine hydrochloride and method for its preparation
CZ2013767A3 (en) 2013-10-02 2015-04-29 Zentiva, K.S. Solid form of ivabradine hydrochloride and (S)-mandelic acid as well as pharmaceutical composition thereof
WO2015001133A1 (en) 2013-12-12 2015-01-08 Synthon B.V. Pharmaceutical composition comprising amorphous ivabradine
SI2774606T1 (en) 2014-02-14 2019-05-31 Synthon B.V. Pharmaceutical composition comprising ivabradine hydrochloride polymorph IV
CZ305436B6 (en) 2014-07-10 2015-09-16 Zentiva, K.S. Solid form of ivabradine hydrochloride and (R)-mandelic acid and pharmaceutical composition thereof
WO2016102423A1 (en) 2014-12-22 2016-06-30 Ratiopharm Gmbh Composition comprising ivabradine in a dissolved form
GR1008821B (en) 2015-06-11 2016-08-01 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Pharmaceutical composition comprising ivabradine hydrochloride and method for preparation thereof
CN107056706B (en) * 2015-12-21 2020-05-05 江苏恒瑞医药股份有限公司 Method for preparing ivabradine hydrochloride α crystal form
WO2017173458A1 (en) * 2016-04-01 2017-10-05 Swiderski Cyprianna Compositions and methods targeting hcn channels for breathing therapeutics
TR201703066A2 (en) 2017-02-28 2018-09-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Solid oral pharmaceutical compositions of ivabradine
EP3366282A1 (en) 2017-02-28 2018-08-29 Sanovel Ilac Sanayi ve Ticaret A.S. Solid oral pharmaceutical compositions of ivabradine
US20230181472A1 (en) 2018-10-30 2023-06-15 Amgen Inc. Process of making ivabradine hydrochloride drug product
CA3161960A1 (en) 2019-12-16 2021-06-24 Tenax Therapeutics, Inc. Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (ph-hfpef)
IT202000025312A1 (en) 2020-10-26 2022-04-26 Cambrex Profarmaco Milano S R L PROCESSES FOR THE PREPARATION OF IVABRADINE HCL POLYMORPHS
US20250064799A1 (en) 2021-12-31 2025-02-27 Tenax Therapeutics, Inc. Oral formulations of levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4490369A (en) * 1981-05-19 1984-12-25 Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung Benzazepine derivatives, their pharmaceutical compositions and method of use
DE3119874A1 (en) * 1981-05-19 1982-12-09 Dr. Karl Thomae Gmbh, 7950 Biberach "BENZAZEPINE DERIVATIVES, THEIR PRODUCTION AND THEIR USE AS MEDICINAL PRODUCTS"
DE69133158T2 (en) 1990-08-29 2003-07-17 Humanetics Corp TREATMENT METHOD FOR PROMOTING WEIGHT LOSS USING A SUBSTITUTED DELTA-5 ANDROSTEN
FR2681862B1 (en) * 1991-09-27 1993-11-12 Adir Cie NOVELS (BENZOCYCLOALKYL) ALKYLAMINES, THEIR PREPARATION PROCESS, AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
FR2818552B1 (en) 2000-12-26 2003-02-07 Servier Lab SOLID THERMOFORMABLE PHARMACEUTICAL COMPOSITIONS FOR THE CONTROLLED RELEASE OF IVABRADINE
FR2834896B1 (en) * 2002-01-23 2004-02-27 Servier Lab ORODISPERSIBLE PHARMACEUTICAL COMPOSITION OF IVABRADINE
FR2868777B1 (en) * 2004-04-13 2006-05-26 Servier Lab NOVEL PROCESS FOR THE SYNTHESIS OF IVABRADINE AND ITS SALTS OF ADDITION TO A PHARMACEUTICALLY ACCEPTABLE ACID
FR2882553B1 (en) * 2005-02-28 2007-05-04 Servier Lab CRYSTALLINE BETA FORM OF IVABRADINE HYDROCHLORIDE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
FR2882554B1 (en) * 2005-02-28 2007-05-04 Servier Lab IVABRADINE HYDROCHLORIDE BETA D-CRYSTALLINE FORM, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
FR2882555B1 (en) * 2005-02-28 2007-05-04 Servier Lab CRYSTALLINE GAMMA FORM OF IVABRADINE HYDROCHLORIDE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
FR2882556B1 (en) * 2005-02-28 2007-05-04 Servier Lab CRYSTALLINE GAMMA D FORM OF IVABRADINE HYDROCHLORIDE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
FR2891826B1 (en) * 2005-10-11 2007-12-28 Servier Lab CRYSTALLINE FORM 6 OF IVABRADINE HYDROCHLORIDE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
FR2891827B1 (en) * 2005-10-11 2007-12-28 Servier Lab CRYSTALLINE DELTAD FORM OF IVABRADINE HYDROCHLORIDE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME

Also Published As

Publication number Publication date
CY1109072T1 (en) 2014-07-02
ME01408B (en) 2010-06-30
KR20060095501A (en) 2006-08-31
TWI314144B (en) 2009-09-01
ECSP066373A (en) 2006-10-17
US7879842B2 (en) 2011-02-01
GT200600084A (en) 2006-11-22
CA2537414C (en) 2010-02-16
AU2006200856A1 (en) 2010-01-28
TW200640873A (en) 2006-12-01
EA008464B1 (en) 2007-06-29
EP1695965B9 (en) 2009-03-04
ATE407926T1 (en) 2008-09-15
FR2882553B1 (en) 2007-05-04
ECSP066375A (en) 2006-11-16
SI1695965T1 (en) 2009-02-28
HRP20080520T3 (en) 2009-01-31
IL173957A0 (en) 2006-07-05
KR100827502B1 (en) 2008-05-06
US7361649B2 (en) 2008-04-22
US20060194962A1 (en) 2006-08-31
PT1695965E (en) 2008-10-08
CN1827600A (en) 2006-09-06
ZA200601762B (en) 2007-04-25
CR8248A (en) 2008-10-06
AP1907A (en) 2008-10-23
FR2882553A1 (en) 2006-09-01
UA80904C2 (en) 2007-11-12
CU23614B7 (en) 2011-01-27
JO2548B1 (en) 2010-09-05
MY158128A (en) 2016-08-30
WO2006092493A1 (en) 2006-09-08
CA2537414A1 (en) 2006-08-28
MA28131A1 (en) 2006-09-01
CO5770096A1 (en) 2007-06-29
PL1695965T3 (en) 2009-01-30
AR053147A1 (en) 2007-04-25
BRPI0600623A (en) 2006-10-24
DE602006002624D1 (en) 2008-10-23
ES2313581T3 (en) 2009-03-01
NO20060946L (en) 2006-08-29
PE20061009A1 (en) 2006-11-18
AP2006003519A0 (en) 2006-02-28
JP4625776B2 (en) 2011-02-02
CU20060039A7 (en) 2008-06-30
HK1096387A1 (en) 2007-06-01
SA06270038B1 (en) 2010-03-29
EP1695965B1 (en) 2008-09-10
NZ545576A (en) 2007-01-26
EP1695965A1 (en) 2006-08-30
DK1695965T3 (en) 2008-12-15
CN1827600B (en) 2010-08-11
EA200600322A1 (en) 2006-08-25
JP2006241154A (en) 2006-09-14
RS50661B (en) 2010-06-30
US20100041640A1 (en) 2010-02-18
NO338370B1 (en) 2016-08-15
US20080161285A1 (en) 2008-07-03
GEP20084465B (en) 2008-08-25
SG125228A1 (en) 2006-09-29

Similar Documents

Publication Publication Date Title
UY29405A1 (en) IVABRADINE CHLORHYDRATE BETA CRYSTAL FORM, ITS PREPARATION PROCEDURE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN IT.
UY29406A1 (en) GAMMA CRYSTAL FORM OF IVABRADINE CHLORHYDRATE, ITS PREPARATION PROCEDURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT.
UY29407A1 (en) GAMMA-D CRYSTAL FORM OF IVABRADINE CHLORHYDRATE, ITS PREPARATION PROCEDURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT.
UY29404A1 (en) BETA-D CRYSTALINE FORM OF IVABRADINE CHLORHYDRATE, ITS PREPARATION PROCEDURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT.
CL2007002610A1 (en) COMPOUNDS DERIVED FROM REPLACED BIPIRIDINE; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT AND / OR PROFILAXIS OF DISEASES SUCH AS HYPERTONIA, DIABETES, MYOCARDIAL INFARTS, BETWEEN OTHERS.
ECSP066914A (en) CRYSTAL FORM OF THE IVABRADINE CHLORHYDRATE, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING IT
CL2009000349A1 (en) Compounds derived from 4,5-dihydro-oxazol-2-ylamine; preparation procedure; pharmaceutical composition; and its use for the treatment of Alzheimer's disease.
ECSP088859A (en) NEW CRYSTAL FORM VI OF AGOMELATINE, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING IT
JO2686B1 (en) compounds
CL2013003262A1 (en) Compounds derived from 1,3-oxazines, with inhibitory activity of bace 1 and / or bace2; pharmaceutical composition comprising them; preparation procedure; Use in the treatment of Alzheimer's disease, diabetes, arterial thrombosis, cancer, myocardial infarction, among other pathologies.
PL2150530T3 (en) Substituted sulfonamide derivatives
GB0522311D0 (en) Pharmaceutical compositions for the treatment of pain
CO6690805A2 (en) 6-amino-nicotinamides substituted as modular of kcnq2 / 3
CL2008001820A1 (en) Aryl-isoxasol-imidazole derived compounds; preparation procedure; pharmaceutical composition containing them; and use in the preparation of useful drugs in the treatment of cognitive disorders and Alzheimer's-related diseases.
CL2010001123A1 (en) Use of pyridin-3-ylmethyl docosahexanoate to prepare a useful medicine for the prevention and / or treatment of cardiovascular diseases (divisional application 1848-07).
CL2008000629A1 (en) MACROCICLICAL COMPOUNDS DERIVED FROM 6-ARIL-4-MERCAPTO- [1.3.5] TRIAZINA / [1.3] PIRIMIDIN-2-AMINA; PHARMACEUTICAL COMPOSITION, USEFUL IN THE TREATMENT OF CANCER.
MX2009008084A (en) 5,6,7,8-tetrahydropteridine derivatives as hsp90 inhibitors.
HK1124863A1 (en) Inhibitors of sodium glucose co-transporter 2 and methods of their use
MY150098A (en) Benzylpiperazine derivates and their medical use
CL2008000982A1 (en) COMPOUNDS DERIVED FROM 5-OXO-ISOXAZOL-CARBOXAMIDA; PREPARATION PROCESS; PHARMACEUTICAL COMPOSITION; PROCEDURE OF PRODUCTION OF THE PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT AND / OR PREVENTION OF ATEROSCLEROTIC DISORDERS, OF METABOLISM OF
PA8798401A1 (en) CRYSTAL FORM 1 OF 2 - ((R) -2-METHYL-PIRROLIDIN-2-IL) -1H-BENZIMIDAZOL-4-CARBOXAMIDA
CL2008003933A1 (en) Compounds derived from n-heterocyclo- [1,2-a] -pyridine-2-carboxamide; preparation procedure; pharmaceutical composition; Useful in the treatment and / or prevention of neurodegenerative and inflammatory diseases, epilepsy, osteoporosis, malignant tumors, among others.
PE20090367A1 (en) CRYSTALLINE FORMS A AND B OF THE COMPOUND 3- (2R-TETRAHYDROFURYL-METHYL) -2-THIOXANTHINE
NZ598174A (en) Fgf receptor-activating n-acyl octasaccharides, preparation thereof, and therapeutic use thereof
CL2007003834A1 (en) COMPOUNDS DERIVED FROM S-NITROSOTIOL; SYNTHESIS PROCEDURE; INTERMEDIARY COMPOUNDS; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DISEASES MEDITATED BY NITRIC OXIDE SUCH AS HYPERTENSION, THROMBOSIS, AMONG OTHERS.

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20181003